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Abstract
Identification of causal rare variants that are associated with complex traits poses a central challenge on genome-wide
association studies. However, most current research focuses only on testing the global association whether the rare variants
in a given genomic region are collectively associated with the trait. Although some recent work, e.g., the Bayesian risk index
method, have tried to address this problem, it is unclear whether the causal rare variants can be consistently identified by
them in the small-n-large-P situation. We develop a new Bayesian method, the so-called Bayesian Rare Variant Detector
(BRVD), to tackle this problem. The new method simultaneously addresses two issues: (i) (Global association test) Are there
any of the variants associated with the disease, and (ii) (Causal variant detection) Which variants, if any, are driving the
association. The BRVD ensures the causal rare variants to be consistently identified in the small-n-large-P situation by
imposing some appropriate prior distributions on the model and model specific parameters. The numerical results indicate
that the BRVD is more powerful for testing the global association than the existing methods, such as the combined
multivariate and collapsing test, weighted sum statistic test, RARECOVER, sequence kernel association test, and Bayesian risk
index, and also more powerful for identification of causal rare variants than the Bayesian risk index method. The BRVD has
also been successfully applied to the Early-Onset Myocardial Infarction (EOMI) Exome Sequence Data. It identified a few
causal rare variants that have been verified in the literature.
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Introduction
Testing the phenotypic association of millions of individual
SNPs across the genome has been one of the major goals of the
genome-wide association study (GWAS). To date, hundreds of
putative disease gene loci have been detected based on the
common disease common variant assumption. However, the
detected genetic variants typically account for only a small fraction
of disease heritability. Nowadays, it has been widely acknowledged
that the missing disease heritability may be due to rare variants.
Many studies show that the rare variants tend to have larger effects
than common variants. As pointed out in [1], most rare variants
can have much greater odds ratio than common variants, and
many non-synonymous rare mutations from exon sequencing are
functional variants for some common diseases. The rare variant
effects have been investigated in some studies. For example, [2]
found that the rare variants in the IFIH1 gene are strongly
associated with Type I diabetes, and [3] found that multiple rare
variants in NPC1L1 are associated with reduced sterol absorption
and plasma low density lipoprotein levels. Therefore, development
of statistical methods that are powerful enough to detect causal
rare variants has become essential for the GWAS.
The statistical power of genetic variant detection depends on the
sample size, the variant effect and the minor allele frequency
(MAF). Since the MAF of the rare variant is low, the single variant
testing-based methods, such as the x2-test and Fisher’s exact test,
that are traditionally used in common variant association studies,
tend to have a low power. To address this issue, methods that test
the collective effect of rare variants for a given genomic region
have been developed, see e.g., the combined multivariate and
collapsing (CMC) test [4], weighted sum statistic (WSS) test [5],
and sequence kernel association test (SKAT) [6]. The CMC and
WSS tests are variant pooling methods, in which the rare variants
are collapsed or summed into a super-variant and then the disease
association is tested with this super-variant. Their power can
depend on the weighting scheme they employed, which often
emphasizes low frequency alleles in controls. Numerous alternative
methods [7,8] are largely their variations. The SKAT test is
developed based on random effect models, which assumes a
common distribution for the genetic effects of variants at different
sites and tests for the null hypothesis that the distribution has zero
variation.
Although testing the collective effects of rare variants is
challenging, identifications of the rare variants which, if any, are
driving the association (i.e., the so-called causal rare variants) is
even more challenging and scientifically more interesting. Along
this research direction, some methods have been developed, e.g.,
the RARECOVER method [9], variable threshold (VT) method
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[10], evolutionary mixed model for pooled association testing
(EMMPAT) method [11], hierarchical generalized linear model
(HGLM) method [12,13], and Bayesian risk index (BRI) method
[14]. The RARECOVER method uses a greedy search algorithm
to determine an association set of variants. The VT method selects
all variants with the MAF lower than a varying threshold to be
included in the association set. The RARECOVER and VT focus
mainly on the global association test and lack a formal test to
determine the marginal effect of each variant, and thus are unable
to formally determine which variants are most likely driving the
association. The EMMPAT simultaneously evaluates the effects of
all variants under the framework of mixed effect models. This is
similar to HGLM, where the regression coefficients are simulta-
neously estimated for all variants. As a consequence of the
simultaneous parameter estimation, when the number of variants
is greater than the number of subjects, the variant effects evaluated
by EMMPAT and HGLM might not be very reliable due to the
multicollinearity of variants. The BRI is a Bayesian method, which
can evaluate the marginal effect of each variant by allowing for
uncertainty into which variants are included in the association set.
While BRI has made a solid step toward detection of causal rare
variants, it is unclear whether it can identify causal rare variants
consistently for small-n-large-P problems, in which the number of
variants can be much greater than the number of subjects. In
addition, BRI assumes the effect of each causal variant to be the
same. Since this is not true for real problems, the performance of
BRI may be sub-optimal. In this paper, we propose a new
Bayesian method, the so-called Bayesian Rare Variant Detector
(BRVD), for identification of causal rare variants. The new
method simultaneously answers two questions:
N (Global association test) Are there any of the variants
associated with the disease?
N (Causal variant detection) Which variants, if any, are driving
the association?
The BRVD ensures the causal rare variants to be consistently
identified in the small-n-large-P situation by imposing some
appropriate prior distributions on the model and model specific
parameters. In addition, to enhance detection of causal rare
variants, the BRVD specifies for each variant a different prior
selection probability (or weight) which is adversely proportional to
its MAF. To accelerate the computation, we also propose a
parallel version of BRVD based on the strategy of divide-and-
conquer. The parallel BRVD has an embarrassingly parallel
structure and can be conveniently applied to the problems for
which the number of variants is extremely large. Our numerical
results indicate that the BRVD can be more powerful for testing
the global association than the existing methods, such as CMC,
WSS, SKAT, C-alpha, RARECOVER, VT, and BRI, and more
powerful than BRI for identification of causal rare variants. The
BRVD has also been successfully applied to the early-onset
myocardial infarction (EOMI) data: It identified a few causal rare
variants that have been verified in the literature.
Materials and Methods
The global association test and Bayesian factor
Assume that n subjects are sequenced in a genomic region with
P SNPs. Let X be a n|P genotype matrix coded as Xij~0,1,2 for
the number of copies of the minor allele measured for individual i
at SNP j, let Z be a n|q matrix of covariates, e.g., age and race,
and let Y be a n-dimensional binary vector indicating the disease
status of the n subjects. The BRVD uses a logistic regression model
to relate the covariates and a subset of variants to the disease status
variable. Let j denote a subset of variants, and let DjD denote the
number of variants included in j. Let Mj denote the logistic
regression model corresponding to the subset j, which can be
expressed as
logitP(Y~1DMj)~a0zZ azXj bj, ð1Þ
where Xj denotes the genotype matrix corresponding to the subset
j, and a0, a~(a1, . . . ,aq) and bj~(b
j
1, . . . ,b
j
DjD) are the regression
coefficients. For this model, the global association test is to test the
hypotheses
H0 : DjD~0 versus H1 : DjDw0: ð2Þ
Let V0 denote the parameter space of the null model M0, i.e., the
domain of the parameters a0 and a. Let V1 denote the parameter
space of the alternative models, which can be expressed as
V1~V0||Mj[MVj, where M denotes the set of all possible
models with DjDw0 and Vj is the domain of bj.
Let p(a0, a) denote the prior distribution of (a0, a), let
p(MjDH1) denote the prior probability imposed on the model
Mj under the hypothesis H1, and let p(bjDMj,H1) denote the
prior distribution of bj. Then the Bayesian factor for the test (2)
can be expressed as
BF (H1 : H0)~
P
Mj[M p(Mj DH1)
Ð
f1(Y Da0, a,Mj, bj)p(a0, a)p(bj DMj,H1)da0d ad bjÐ
f0( Y Da0, a)p(a0, a)da0d a
~
D p(DDH1)
p(DDH0) ,
ð3Þ
where f0(:) and f1(:) denote the likelihood functions of the null and
alternative models, respectively; D denotes the data; and p(DDH1)
and p(DDH0) are the Bayesian evidence corresponding to the
hypotheses H1 and H0, respectively. As in [14,15], (3) can also be
expressed as the weighted average of the individual Bayes factors
for comparing each model in H1 to the null model M0 with the
weights given by the prior probability p(MjDH1); that is,
BF (H1 : H0)~
X
Mj[M
p(MjDH1)BF (Mj : M0), ð4Þ
where BF (Mj : M0) is defined as the ratio ofÐ
f1(Y Da0, a,Mj, bj)p(a0, a)p(bjDMj,H1)da0d ad bj andÐ
f0(Y Da0, a)p(a0, a)da0d a. Let p(H0) denote the prior proba-
bility imposed on the null model, and let p(H1)~1{p(H0) denote
the total prior probabilities imposed on the alternative models.
Then the respective posterior probabilities of H0 and H1 are given
by
p(H0D )~
p(H0)
p(H0)zp(H1)BF (H1 : H0)
, p(H1D )~1{p(H0D ):
A value of BF(H1 : H0)w1 means that the alternative hypothesis
is more strongly supported by the data under consideration than
the null hypothesis. Harold Jeffreys [16] gave a scale, which is
reproduced in Table 1, for interpretation of Bayes factors.
Decisions about which hypothesis is more likely true can be made
based on the scale of Bayes factors.
The Bayes factor (3) depends on the prior distributions, p(a0, a),
p(MjDH1), and p(bjDMj,H1). In particular, the dependence on the
model prior p(MjDH1) can be substantial. This inevitably leads to
ð3Þ
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ambiguity in interpretation of Bayes factors. To minimize the
ambiguity, we suggest to choose the priors p(MjDH1) and
p(bjDMj,H1) such that the Bayesian evidence of H1 is maximized.
The resulting prior is the so-called type-II maximum likelihood
prior [17]. Since maximizing the evidence over general priors is
impossible, we further suggest to maximize the evidence over a
specified class of priors. This will be detailed below. We note that a
similar strategy has been suggested in [18] for testing a point null
hypothesis. Since a0 and a are common parameters for all models,
p(a0, a) is fixed to a Gaussian-truncated-inverse-gamma prior in
all simulations of this paper.
The prior and posterior distributions
Let ai, i~0,1, . . . ,q, be subject to the independent Gaussian
prior:
ai*N(0,s2a), i~0,1, . . . ,q, ð5Þ
where the variance s2a is subject to a truncated inverse-gamma
prior
s2a*IG(a,b;A,B), ð6Þ
defined on the interval ½A,B, where a and b are the shape and
scale parameters, respectively. The density function of (6) is given
by
f (s2a)~
1
Q(a,b=A){Q(a,b=B)
ba
C(a)
e{b=s
2
a
s
2(az1)
a
,
where Q(a,x)~
Ð x
0
e{tta{1dt=C(a) is an incomplete gamma
function and can be evaluated numerically. In the literature, s2a
is usually assumed an inverse-gamma prior distribution. Here s2a is
restricted to take values from the bounded interval ½A,B. As
shown in Lemma 1 of File S1 (Section S1), this restriction plays an
important role in establishing the posterior consistency [19,20] for
the model (1). The posterior consistency means the true density of
Y can be estimated consistently by the density of Y under the
models sampled from the posterior distribution. For the same
reason, we let bj1, . . . ,b
j
DjD be subject to the independent Gaussian
prior
bji*N(0,s
2
b), i~1,2, . . . ,DjD, ð7Þ
with the variance s2b being subject to the truncated inverse-gamma
prior IG(a,b;A,B). For simplicity of computation, we further
assume s2a~s
2
b; that is, ai and b
j
i have the same prior variance.
Let ni denote the prior selection probability of variant i. Let
dj(i)~1 if variant i is included in the subset j and 0 otherwise.
The prior probability of the model Mj under H1 is given by
p(MjDH1)~
PPi~1 n
dj(i)
i (1{ni)
1{dj(i)
1{PPi~1 (1{ni)
: ð8Þ
To enhance selection of causal rare variants, we suggest to set ni as
a decreasing function of MAF. In this paper, we set
ni~
1
1zPci
, ð9Þ
where ci is restricted to the interval ½E,1) for some constant Ew0.
In this paper, we set ci~c
Lz(cR{cL)(log(MAFi){
minj log(MAFj))=(maxj log(MAFj){minj log(MAFj)), where
MAFi denotes the minor allele frequency of variant i, and c
L and
cR are hyperparameters to be specified by the user. In addition, we
fix cR~0:99 and choose cL[½E,cR such that the Bayes factor
BF(H1 : H0) is maximized. Note that (9) is not necessarily optimal.
In practice, one may try different settings for ci and c
R.
As shown in File S1 (Section S1), the above prior setting,
together with the identifiability condition of the true model, leads
to the consistency of causal variant selection. Our priors are
different from the conventional ‘‘Gaussian–inverse-gamma–beta’’
priors in two aspects. First, we let s2a and s
2
b be subject to the
truncated inverse-gamma prior, which ensures the eigenvalues of
the prior covariance matrix of (a0,a1, . . . ,aq,b
j
1, . . . ,b
j
DjD) to be
bounded. While the boundedness condition cannot be achieved
with the inverse-gamma prior. Second, we define ni in (9) as a
decreasing function of P. As explained in [21], this is important for
variant selection in the small-n-large-P scenario, because it
controls for the multiplicity: If P grows large, then ni?0. Under
appropriate conditions, it can be shown that the resulting a priori
model size
PP
i~1 ni is bounded by a function (of n) of order o(n
f)
for some fv1. While this condition cannot be satisfied if ni is
subject to a beta prior for which both the shape and scale
parameters are constants independent of n.
Let p(H0) and p(H1) denote the prior probabilities imposed on
H0 and H1, respectively. Then the posterior distribution of the
model (1) is given by
p(a0, a ,Mj, b j D )~
p(H1)p(a0, a,Mj, bj,DDH1)I(DjD§1)zp(H0)p(a0, a,DDH0)I(DjD~0)
p(H1)p(DDH1)zp(H0)p(DDH0) ,ð10Þ
where I(:) is the indicator function, and p(a0, a,Mj, bj,DDH1)
and p(a0, a,DDH0) are given in File S1 (Section S0).
In all simulations of this paper, we fixed the hyperparameters
a~1, b~1, A~0:01, B~100:0, and cR~0:99. The choice of a,
b, A and B allows s2 to vary over the interval ½0:01,100 which is
large enough for most rare variant selection problems. The only
remaining hyperparameter is cL, which can be determined by
maximizing the Bayes factor BF(H1 : H0) over the interval ½E,cR.
For most examples of this paper, we tried cL=0.4, 0.5, …, 0.9,
0.95, 0.99 or a subset of them.
Table 1. Jeffrey’s grades of evidence (Jeffreys, 1961).
Grade BF(H1:H0) p(H1|D)
Evidence against
H0
1 1,3 0.50,0.75 Barely worth
mentioning
2 3,10 0.75,0.91 Substantial
3 10,30 0.91,0.97 Strong
4 30,100 0.97,0.99 Very strong
5 .100 .0.99 Decisive
The posterior probability p(H1 D ) is calculated with the prior probabilities
p(H0)~p(H1)~1=2.
doi:10.1371/journal.pone.0069633.t001
ð10Þ
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Bayes factor estimation
For the global association test, the key step is Bayes factor
estimation. As implied by (4), an exact evaluation of the global
Bayes factor needs to sum over all models under H1. When P is
large, this is prohibitive. For this reason, [14,15] suggested to
replace the sum over the entire model space M with the sum over
the models sampled by a Markov chain Monte Carlo (MCMC)
algorithm. However, the resulting estimator is shown to provide
only a lower bound for the global Bayes factor. In this paper, we
propose to estimate the global Bayes factor using the stochastic
approximation Monte Carlo (SAMC) algorithm [22]. The
resulting estimator is consistent.
To facilitate the description of the SAMC algorithm, we define
the following notations. Let v~(a0, a,Mj, bj,H1) for a model
simulated from the posterior distribution (10) under H1, and let
v~(a0, a,H0) for a model simulated under H0. Define
y(v)~
p(H1)p(a0, a,Mj, bj,DDH1), under H1,
p(H0)p(a0, a,DDH0), under H0,
 
which is the unnormalized posterior distribution of the model (1).
Let U(v)~{logy(v), which is called the energy function in
terms of physics. To apply the SAMC algorithm to estimate the
Bayes factor, we partition the sample space as follows: Treat V0 as
a single subregion, i.e., setting E0~fv : DjD~0,v[V0|fH0gg,
and partition V1 according to the energy function into m
subregions: E1~fv : U(v)ƒu1,v[V1|fH1gg,
E2~fv : u1vU(v)ƒu2,v[V1|fH1gg, …,
Em{1~fv : um{2vU(v)ƒum{1,v[V1|fH1gg,
Em~fv : U(v)wum{1,v[V1|fH1gg, where u1, . . . ,um{1 are
pre-specified numbers. The sample space V1 can also be
partitioned according to the value of DjD. However, when P is
large, this alternative partition often leads to a slower convergence
of SAMC, as which encourages SAMC to sample the models of
different sizes instead of those of low energy values.
SAMC seeks to draw samples from each of the subregions with
a pre-specified frequency. For the time being, we assume that all
the mz1 subregions are non-empty; that is,
Ð
Ei
y(v)dvw0 for
i~0,1, . . . ,m. Let p~(p0,p1, . . . ,pm) denote the vector of desired
sampling frequencies of the mz1 subregions, where 0vpiv1 andPm
i~0 pi~1. Henceforth, p is called the desired sampling
distribution. Let hi~log(
Ð
Ei
y(v)dv=pi) for i~0,1 . . . ,m, let
h~(h0,h1, . . . ,hm), and let H denote the domain of h. Let
h(t)~(h(t)0 ,h
(t)
1 , . . . ,h
(t)
m ) denote the working estimate of h obtained
at iteration t. Let v(tz1) denote a sample drawn at iteration tz1
from the MH kernel Kh(t) (v
(t),:), which is constructed with the
proposal distribution T(v(t),:) and admits (11) as the invariant
distribution:
f
h(t)
(v)!
Xm
i~0
y(v)
e
h
(t)
i
I(v[Ei): ð11Þ
Define R(h(t),v(tz1))~e(tz1){p, where
e(tz1)~(e(tz1)0 , . . . ,e
(tz1)
m ) and e
(tz1)
i ~1 if v
(tz1)[Ei and 0
otherwise. Note that the dependence of R(:,:) on h(t) is implicit
through the sample v(tz1). To have the algorithm complied with
the notation of stochastic approximation, h(t) is still included in the
function R(:,:). Let fatg be a positive, non-decreasing sequence
satisfying the conditions,
(i)
X?
t~0
at~?, (ii)
X?
t~0
attv?, ð12Þ
for some t[(1,2. In the context of stochastic approximation,
fatgt§0 is called the gain factor sequence.
In this paper, we assume that H is compact; that is, assuming
that the sequence fh(t)g can be kept in a compact set. Extension of
this algorithm to the case that H~Rmz1 is trivial with the
technique of varying truncations studied in [23,24], which ensures,
almost surely, that the sequence fh(t)g remains in a compact set. In
simulations, we can set H to a huge set, e.g.,
H~½{10100,10100mz1, which, as a practical matter, is equivalent
to setting H~Rmz1. Let J(v) denote the index of the subregion
that the sample v belongs to, which takes values in f0,1, . . . ,mg.
With the above notations, one iteration of SAMC can be described
as follows.
Algorithm 0.1 (The SAMC algorithm)
(a) (Sampling) Simulate a sample v(tz1) by a single MH update with the
target distribution as defined in (11):
(a. 1) Generate v’ according to a proposal distribution T(v(t),v’). Refer
to File S1 (Section S2) for the definition of T(v(t),v’).
(a. 2) Calculate the ratio
r~e
h
(t)
kt
{h
(t)
k’
y(v)T(v’,v(t))
y(v(t))T(v(t),v’)
, ð13Þ
where kt~J(v
(t)) and k’~J(v’) are the indices of the subregions that v(t)
and v’ belong to, respectively.
(a. 3) Accept the proposal with probability min(1,r). If it is accepted, set
v(tz1)~v’; otherwise, set v(tz1)~v(t).
(b) (h-updating) Set
h(tz
1
2
)
~h(t)zatz1R(h
(t),v(tz1)): ð14Þ
If h(tz
1
2
)[H, set h(tz1)~h(tz
1
2
)
; otherwise, find a value of c such that
h(tz
1
2
)
zc1mz1[H and set h(tz1)~h
(tz1
2
)
zc1mz1, where 1mz1
denotes a constant (mz1)-vector of ones.
SAMC is an adaptive MCMC algorithm for which the invariant
distribution of the MH kernel changes from iteration to iteration.
Due to the adaptive change of the invariant distributions, SAMC
possesses a self-adjusting mechanism: If a proposal is rejected, then
the sample v(tz1) will be retained in the current subregion, the h-
value associated with the current subregion will be adjusted to a
larger value, and the overall rejection probability of the next
iteration will be reduced. This mechanism warrants the algorithm
not to be trapped by local energy minima. The SAMC algorithm
represents a significant advance in simulations of complex systems
for which the energy landscape is rugged.
The proposal distribution T(v,v’) is usually assumed to satisfy
the local positive condition: For every v[V, there exist E1w0 and
E2w0 such that
Ev{v’EƒE1[T(v,v’)§E2, ð15Þ
where Ev{v’E denotes a distance norm between v and v’. This
is a natural condition in MCMC theory. In practice, this kind of
proposals can be easily designed for both discrete and continuum
systems as discussed in the literature [22]. Regarding the
Bayesian Detection of Causal Rare Variants
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convergence of SAMC, [22] established the following result:
Under the conditions (12) and (15) and some regularity conditions,
for all non-empty subregions,
h(t)i ?C0zlog
ð
Ei
y(v)dv
 !
{log pizpeð Þ, a:s:, ð16Þ
as t??, where pe~
P
j[fi:Ei~1g pj=(mz1{m0),
m0~#fi : Ei~1g is the number of empty subregions, and C0
is a constant which can be determined by imposing a constraint on
h(t)i , e.g.,
Pm
i~0 exp(h
(t)
i )~1.
For global association tests, we set the desired sampling
distribution to be uniform, i.e., setting
p0~p1~   ~pm~1=(mz1). For mathematical simplicity, we
have constrained V0 and V1 to two large compact sets by
restricting (a0, a, bj) to the set ½{10100,101001zqzDjD, which, as a
practical matter, is equivalent to R1zqzDjD. The gain factor
sequence fatg is set in the form
at~
t
maxft,t0g , ð17Þ
where t0w0 is a user-specified number. It is easy to verify that (17)
satisfies the condition (12). A large value of t0 will allow the SAMC
sampler to reach all subregions quickly, even when m is large. The
proposal distribution T(v,v’) is described in File S1 (Section S2).
It is easy to see that it satisfies the condition (15). Then, by (16), we
have the following result:
Pm
i~1 e
h
(t)
i
e
h
(t)
0
?BF (H1 : H0), a:s:, ð18Þ
as t??. That is, SAMC provides a consistent estimator for the
Bayes factor.
Rare variant detection
In this section, we describe how to detect rare variants when the
global association test shows positive support for the hypothesis
H1.
Identification of important variables based on the marginal
inclusion probability has been widely used in Bayesian variable
selection, see, for example, [25] for the case of large-n-small-P
normal linear models, and [26] for small-n-large-P generalized
linear models. Let qj denote the marginal inclusion probability of
variable j. A conventional rule is to choose the variables for which
the marginal inclusion probability is greater than a threshold value
q^; i.e., setting bjq^~fxj : qjwq^,j~1, . . . ,Png as an estimator of j,
the set of true model variables. Based on [26], we show in Lemma
2 of File S1 (Section S1) that this rule possesses the properties of
sure screening and consistency for rare variant detection under the
priors given in Section 0. The sure screening property implies that
for some choice of q^[(0,1),
P(j5bjq^)?1,
as the sample size n tends to infinity. The property of variant
selection consistency implies that
P(j~bj0:5)?1,
as the sample size n tends to infinity.
To implement the rule bjq^ for causal variant detection, one needs
a consistent estimator for the marginal inclusion probability under
H1 and a method for determining the threshold value q^. In
SAMC, the marginal inclusion probability can be consistently
estimated as follows. Let (v(1), h(1)), . . . ,(v(N), h(N)) denote the
samples drawn by SAMC in a run. Liang [27] showed that SAMC
is actually a dynamic importance sampling algorithm and for any
integrable function r(v), as N??,
PN
t~1 e
h
(t)
J(v(t))r(v(t))PN
t~1 e
h
(t)
J(v(t))
?Epr(v), a:s:, ð19Þ
where Epr(v) denotes the expectation of r(v) with respect to the
target distribution p(vD ). This result implies
q^j~
PN
t~1 e
h
(t)
J(v(t))I(xj[jt)PN
t~1 e
h
(t)
J(v(t))I(DjtD§1)
?qi, a:s:, ð20Þ
as N goes to infinity; that is, the estimator q^j is consistent.
To determine the threshold q^, [26] proposed a multiple
hypothesis testing-based procedure based on the work [28]. This
procedure is adopted in the paper and briefly described in File S1
(Section S3).
Empirical Power Simulations
To explore the power of the proposed method versus other
alternative methods for the global association tests and rare variant
detection, we simulated 200 datasets, with 100 simulated underH0
and 100 under H1. Each dataset consists of 250 cases and 250
controls, and each subject consists of q~2 covariates. The first
covariate is binary, which mimics the gender of the subjects. The
second covariate is drawn uniformly from the interval ½10,85,
which mimics the age of the subjects. The regression coefficients of
the two covariates are set to a1~0:25 and a2~0:01, respectively.
The genotypes of each subject are simulated by resampling from a
haplotype dataset given in the package SKAT. The haplotype
dataset is generated by the calibrated coalescent model with a
mimicking linkage disequilibrium (LD) structure of European
ancestry. To emphasize rare events, the variants with MAF greater
than 5% have been removed from the haplotype dataset before
resampling. For the 100 datasets simulated under H1, the first 10
variants are assumed to be causal with the regression coefficients
given by (2:09,1:90,1:85,1:82,1:57,1:96,1:40,1:93,2:20,2:00),
which represents a random sample drawn from N(2,0:252). Then
we remove the zero-MAF variants from the resampled dataset and
keep only the first 600 non-zero MAF variants for further analysis.
Because of this deletion step, the number of causal variants
becomes a random variable for each dataset. For the 100 datasets
simulated under H1, the number of causal variants ranges from 5
to 9, and has a mean value of 7.81 with standard deviation 0.92.
The average MAF of the first 9 variants is 0.833% with standard
deviation 0.0012. Among the first 9 variants, the maximum MAF
is 1.155%. Variants 1 and 2 have very low MAFs, which are
0.183% and 0.293%, respectively. Due to their low MAFs,
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identification of the causal variants, especially for variants 1 and 2,
has put a great challenge on the existing methods.
Comparison with Other Methods
We compare the BRVD with the competing Bayesian method
Bayesian risk index (BRI) for both global association tests and causal
variant detection. We also compare BRVD with the commonly
used non-Bayesian methods, including CMC, WSS, SKAT, and
RARECOVER, for global association tests. Among the four non-
Bayesian methods, CMC and WSS belong to the class of variant
pooling methods, SKAT belongs to the class of random effect
model-based methods, and RARECOVER belongs to the class of
variable selection methods. These methods can be briefly
described as follows.
N Bayesian risk index (BRI) [14]: For a model Mj, the BRI
defines the risk index as the sum of the selected variants, i.e.,
Rj~X dj,
where dj~(dj(1), . . . ,dj(P))’ is a binary vector which indicates
the variants included in the model Mj. Then it conducts an
approximate Bayesian analysis for the model
logitP(Y~1DMj)~a0zZ azRjbj,
under a Beta-Binomial prior for the model size. The prior
specification for (a0, a,bj) is avoided in BRI, as it directly works
on the marginal likelihood P(Y DMj) with the parameters
(a0, a,bj) replaced by their MLE. The significance of global
association is determined using the Bayes factor calculated in (4)
with posterior samples. The rare variants are selected based on the
marginal Bayes factor which, for any two variants, is defined as the
ratio of the odds of their posterior marginal inclusion probabilities
to the odds of their prior marginal inclusion probabilities.
N Combined multivariate and collapsing (CMC) test [4]: CMC is a
variant pooling method in which the rare variants are grouped
according to their allele frequency. After grouping, the rare
variants are collapsed into an indicator variable, and then a
multivariate test such as Hotelling’s T2 test is applied to the
collection formed by the common variants and the collapsed
super-variant.
N Weighed sum Statistic (WSS) test [5]: WSS is a variant pooling
method. It first calculates for each subject a genetic score,
which accumulates the rare variants counts within the same
gene with a weighting term that emphasizes alleles with a low
frequency in controls. Then the scores for all subjects are
ordered, and the WSS is computed as the sum of the ranks for
the cases. The significance is determined by a permutation
procedure.
N Sequence kernel association (SKAT) test [6]: SKAT is a random
effect model-based method. It assumes a common distribution
for the genetic effects of different variants and test for the null
hypothesis that the distribution has zero variance.
N RARECOVER [9]: RARECOVER is a variable selection-based
method. It selects variants in a manner of forward variable
selection: Starting from a null model without any genetic
variants, the variants are added into the model one by one
based on their statistical significance. The significance of global
association is determined by a permutation procedure.
The implementation of BRI is available in the R package BVS,
the implementation of SKAT is available in the R package SKAT,
and the implementations of CMC, WSS, and RARECOVER are
available in the R package AssotesteR. In this paper, all the
methods are run under their default settings unless otherwise
stated.
Results
Global Power
We first aim to examine the power of the BRVD versus
alternative methods for global association tests. The BRVD has a
prior hyperparameter cL to tune. To determine the value of cL, we
tried the values 0.4, 0.5, …, 0.9, and 0.99 for all the 200 simulated
datasets. For each dataset and each value of cL, SAMC was run
for 5:05|106 iterations, where the first 50000 iterations were for
the burn-in process and the samples generated from the remaining
iterations were used for inference. The gain factor sequence was
set in (17) with t0~1000, and the sample space V1 was partitioned
into m~99 equally spaced (in energy values) subregions with
u1~341 and um{1~439. Figure 1 (a) & (b) show the average
posterior probability p(H1D ,cL) versus cL for the datasets
simulated under H1 and H0, respectively, where the average is
calculated over 100 datasets. To indicate the dependency of the
average posterior probability on cL, we include cL in the notation.
For the datasets simulated under H1, p(H1D ,cL) attains its
maximum at cL~0:6; and for the datasets simulated under H0,
p(H1D ,cL) attains its maximum at cL~0:99. This is interesting: A
small value of cL encourages selection of variants, while a large
value of cL discourages selection of variants. This is consistent with
our design of the study: More variants are preferred to be selected
for the datasets simulated under H1. Figure 1 shows p(H1D ,cL)
versus different values of cL: p(H1D ,cL) changes only about %2
over the interval 0:4ƒcLƒ0:99 for the datasets simulated under
H1, and changes only about 7% for the datasets simulated under
H0. Therefore, we may conclude that the posterior probability
p(H1D ,cL) is quite robust to the choice of cL.
Since BRVD, BRI and SKAT are all developed under the
regression setting, they are able to adjust for covariates, such as
age, gender, race, etc. For this reason, we first compare the powers
of these three methods with the simulated covariates adjusted in
regression. Figure 2 compares the ROC curves for the global
association test, which plots the global false-positive rate (gFPR)
versus global true-positive rate (gTPR) as the global BF threshold
varies for BRVD and BRI, and the p-value threshold varies for
SKAT. As in BRI, the gFPR is calculated as the ratio of the
number of null datasets (the datasets simulated under H0) for
which a global association has been detected versus the total
number of null datasets, and the gTPR is calculated as the number
of associated datasets (the datasets simulated underH1) for which a
global association has been detected versus the total number of
associated datasets. Figure 2(a) shows that for this example, BRVD
has about the same power as SKAT and much greater power than
BRI to detect a global association. Note that in this plot, we have
followed the procedure suggested in Section 2.1 to calculate the
gFPR for the null datasets with cL~0:99 and calculate gTPR for
the associated datasets with cL~0:6. To show the performance of
BRVD is robust to the choice of cL, we plot in Figure 2(b) a few
ROC curves, where for each curve both gFPR and gTPR were
calculated at the same value of cL. The plot indicates that the
BRVD is very robust to the choice of cL for global association
tests.
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The CMC, WSS and RARECOVER cannot be adjusted for
covariates. To compare with them, we re-run the BRVD, BRI and
SKAT methods on the simulated datasets with the covariates
omitted. The effect of covariate omission on test power has been
discussed in the literature [29,30,31]. The results seem mixed.
Under certain situations, such as rare diseases and large sample
sizes, omitting the covariates, which are known to affect disease
susceptibility and are independent of tested genotypes, can
increase the power to detect new genetic associations; whereas,
for common diseases, it can decrease the power [31]. For BRVD,
SAMC was run for these datasets with the same setting as for the
case with covariates adjusted. Figure 3(a) compares the ROC
curves of the six methods for global association tests. It shows that
when covariates are omitted, BRVD has much greater power than
all other methods. Compared to Figure 2(a), we may conclude that
BRVD is more robust to covariate omission than the SKAT
method. This is important for the success of a method, as in
practice we may inevitably have some covariates omitted due to
the limitation of our measurements. Figure 3(b) compares the
ROC curves of BRVD calculated with different values of cL. It
shows again that the power of BRVD is robust to the choice of cL
for global association tests.
In addition to the power, we also explored the type-I error of
the global association test based on the testing statistic
maxcL[L p(H1D ,cL) for the simulated examples, where
L~f0:4,0:5, . . . ,0:9,0:99g and the prior probabilities
p(H0)~p(H1)~1=2. The results, for both cases with and without
covariate adjustment, are summarized in Figure 4. Following from
Table 1, we suggest to choose 0.75 as the threshold value of
maxcL[L p(H1D ,cL); that is, rejecting H0 if
maxcL[L p(H1D ,cL)w0:75. With this threshold value, the result-
ing type-I errors are 0.01 and 0.02 for the cases with and without
covariate adjustment, respectively.
Rare Variant Detection
Our next aim is to detect rare variants that are associated with
the disease, provided that the global association test shows a
positive support for the hypothesis H1. Figure 5 compares the
ROC curves of BRVD and BRI for rare variant detection, which
are calculated based on the 100 datasets simulated under H1. The
ROC curves plot the marginal false-positive rate (mFPR) versus
marginal true-positive rate (mTPR) as the marginal inclusion
probability threshold varies for BRVD and the marginal BF
threshold varies for BRI. As in BRI, the mFPR is calculated as the
ratio of the number of non-associated variants for which a
marginal association has been detected versus the total number of
non-associated variants, and the mTPR is calculated as the ratio of
the number of associated variants for which a marginal association
has been detected versus the total number of associated variants.
In drawing Figure 5, the marginal inclusion probabilities for both
BRVD and BRI have been averaged over 100 datasets. The left
panel of Figure 4 shows the ROC curves for the case with
covariates adjusted, and the right panel shows for the case with
covariates omitted. In both cases, the BRVD has much greater
power than BRI for detection of causal rare variants, especially
Figure 1. The average posterior probability p(H1D ,cL) versus cL for the datasets simulated under H1 (plot (a)) and under H0 (plot
(b)).
doi:10.1371/journal.pone.0069633.g001
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when cL is small, e.g., cL~0:4, 0.5 and 0.6. When cL~0:99,
under which all alleles are treated equally, the BRVD has about
the same power as BRI. It is worth noting that the BRVD yields its
worst result at cL~0:99.
For global association tests, we suggest to choose the value of cL
such that the Bayes factor BF(H1 : H0) is maximized. Figure 5
suggests that this is still a reasonable rule for determining the value
of cL even when our aim is to detect causal rare variants. At
cL~0:6, BRVD performs reasonably well: The top 9 variants
(ranked in marginal inclusion probabilities) include 7 causal
variants, and variants 1 and 2 are ranked 22 and 19, respectively.
For this example, we find that a smaller value of cL may result in a
greater power of BRVD to detect causal rare variants. For
example, at cL~0:4, the top 10 variants include all 9 causal
variants, and variants 1 and 2 are ranked 4 and 9, respectively. At
cL~0:5, the top 10 variants include 8 causal variants (1,3–9), and
variant 2 is ranked 15. This is remarkable, as both variants 1 and 2
have very low MAFs. In BRI, although the variants 3–9 have high
ranks in their marginal BFs, variants 1 and 2 are ranked 542 and
68, respectively. This implies that BRI essentially fails to detect
variants 1 and 2. The results of this example suggest an alternative
rule for determining the value of cL: If we aim to detect rare
variants, we may choose a small value of cL such that some rare
variants, such as those singleton variants, can be ranked high in
their marginal inclusion probabilities, provided that the association
set includes some singleton variants in a priori knowledge.
Figure 6 illustrates how to identify causal variants based on their
marginal inclusion scores. The left panel of Figure 6 shows the
result for cL~0:6. At the FDR level of 0.05, 10 variants are
identified as causal variants, and 7 of them (including variants 3–9)
are true causal variants. At the FDR level of 0.01, 7 variants are
identified and 6 of them (variants 4–9) are true. The right panel of
Figure 6 shows the result for cL~0:5. At the FDR level of 0.05, 11
variants are identified as causal variants, and 8 of them (variants 1,
3–9) are true. At the FDR level of 0.01, 7 variants are identified
and 6 of them (variants 4–9) are true. The results for other values
of cL are similar.
Application to the Early-Onset Myocardial Infarction
(EOMI) Exome Sequence Data
The EOMI data (downloaded from dbGaP) is from the
NHLBIJs Exome Sequencing Project (ESP), which was designed
to identify genetic variants in coding regions (exons) of the human
genome that are associated with heart, lung and blood diseases.
The dataset consists of 278,263 SNPs in 905 subjects (467 cases
and 438 controls) with European origin (EA). After removing the
common variants (with MAFw5%) and the variants with zero
MAFs, the number of variants is reduced to 113,438. A direct
application of BRVD to this dataset is time consuming as it may
need an order of 108 iterations. In addition, the whole dataset
need to be scanned once for each iteration. To resolve this issue,
we propose, based on the strategy of divide-and-conquer, the
following procedure:
Figure 2. Global ROC curves for BRVD versus BRI and SKAT for the simulated example (with covariate adjustment). Each plot
represents a ROC curve as we vary the global BF threshold for BRVD and BRI, and vary the p-value threshold for SKAT.
doi:10.1371/journal.pone.0069633.g002
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Parallel BRVD
(a) (Dividing) Divide the variants into subsets that are of an
acceptable size in computation.
(b) (Parallel conquering) Apply BRVD to each of the subsets and
identify putative associated variants from the subsets for which the
hypothesis H1 is supported.
(c) (Combining) Combine the variants identified at step (b) into a
new dataset, the so-called selected subset data; and then apply
BRVD to the selected subset data to identify causal rare variants.
For each subset, the logistic regression model is potentially
misspecified because the causal variants located in other subsets
are not included in the regression. If some causal variants are
missed, we can expect that the BRVD will find some surrogate
variants within the subset for the missing causal variants, and the
number of surrogate variants can often be greater than the
number of missing causal variants. For this reason, we suggest a
high FDR level, say, 0.25 or even higher, to be used for identifying
putative causal variants from each subset. For the selected subset
data, we can expect that it will include the causal variants,
surrogate variants of some causal variants, and some noise
variants. It is obvious that Lemma 1 and Lemma 2 are still
applicable to the selected subset data. By these two lemmas, the
parallel BRVD can also select causal variants consistently.
The global association test can also be done on the selected
subset of variants. However, a direct application of the BRVD to
this subset can lead to a biased test, although for which the power
can be very high. This is the same for all other testing procedures.
To avoid the bias, a permutation method can be used to evaluate
the p-value of the test. For example, one can permute the response
variable a large number of times. For each of permuted datasets,
the parallel BRVD can be applied to identify a selected subset of
variants and then obtain a Bayes factor for the global association
test based on the selected subset. Finally, a p-value can be
calculated based on the Bayes factors of the permuted datasets.
For the EOMI dataset, we divide the variants into 22 subsets
according to the chromosomes where they belong to. The
numbers of variants on the 22 chromosomes range from 1,271
(on chromosome 21) to 11,491 (on chromosome 1), which are all
acceptable to our current computing facility. BRVD was run 5
times for each subset at each value of cL~0:6, 0.7, 0.8 and 0.9,
and each run consisted of 2:5|107 iterations. The gain factor
sequence was set in (17) with t0~5000, and the sample space V1
was partitioned into m~599 equally spaced (in energy values)
subregions with u1~601 and um{1~1199. Table 2 summarizes
the posterior probabilities of H1 for the 22 chromosomes. The
support for the hypothesis H1 is overwhelming:
maxcL[L p(H1D ,cL) is greater than 0.5 for all 22 chromosomes,
where the probability p(H1D ,cL) is calculated by averaging over 5
independent runs and L~f0:6,0:7,0:8,0:9g denotes the set of
values of cL we have tried. According to the value of
maxcL[L p(H1D ,cL), the chromosomes can be classified into two
groups: chromosomes 13, 2, 3 and 19 are in the first group with
maxcL[L p(H1D ,cL)§0:7, and all other chromosomes are in the
second group with 0:5vmaxcL[L p(H1D ,cL)v0:57. Among the
first group chromosomes, chromosomes 13 and 2 provide
‘‘substantial’’ evidence for the global association.
Figure 3. Global ROC curves for BRVD versus BRI, SKAT, CMC, WSS and RARECOVER for the simulated examples (without covariate
adjustment). Each plot represents a ROC curve as we vary the global BF threshold for BRVD and BRI, and vary the p-value threshold for SKAT, CMC,
WSS and RARECOVER.
doi:10.1371/journal.pone.0069633.g003
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Since all chromosomes show positive support for the global
association, putative associated variants should be identified from
each of them. For illustration, we here work on the first group
chromosomes only. Figure 7 illustrates the selection of putative
associated variants from chromosome 13. At a FDR level of 0.25,
24 variants were identified from this chromosome. In the same
procedure, 42, 32, and 39 variants were identified from
chromosomes 2, 3, and 19, respectively. Putting all the selected
variants together form a selected subset of 137 variants.
The BRVD was then applied to the selected subset of variants
with the same setting as described above except for sample space
partitioning and L. For the selected subset data, V1 was
partitioned into m~299 equally spaced (in energy values)
subregions with u1~601 and um{1~899, and the values of c
L
we tried include 0.5, 0.6, …, 0.9. A smaller value of cL was tried
here as P~137 is very small for the selected subset. At each value
of cL, the BRVD shows a decisive support to the hypothesis H1
with the estimate of the posterior probability p(H1D ) being nearly
equal to 1. For example, at cL~0:5, the BRVD produced an
estimate of 1{3:6|10{75 for p(H1D ). As discussed above, this
estimate of p(H1D ) can be biased for the global association test.
At cL~0:5, the BRVD identified 10 variants as causal variants at
the FDR level 0.1, and identified 14 variants as causal variants at
the FDR level 0.2. Table 3 shows the 14 variants in the order
(from high to low) of their marginal inclusion probabilities. Among
the 14 variants, there are two variants with the MAF lower than
1%. The results for other values of cL are similar.
Our method is surprisingly successful for this example: A few
rare variants identified by it have been verified in the literature. It
is reported that SLC1A4 is associated with atherosclerosis [32],
TMEM44 regulates low-density lipoprotein receptor (LDLR)
levels which in turn is a critical factor in the regulation of blood
cholesterol levels [33], GPC6 is associated with breast cancer [34],
and schizophrenia and bipolar [35] and PCBP4 is associated with
lung cancer [36].
For comparison, BRI and SKAT were also applied to this
example. BRI was run for 50,000 iterations for each of the 22
subsets. The outputs show that only chromosome 2 provides
‘‘substantial’’ evidence for the global association with a Bayes
factor of 7.1. The Bayes factors for all other chromosomes are less
than 1. On chromosome 2, BRI identified three SNPs,
rs65245292, rs179455352 and rs28827533, whose marginal Bayes
factor are all greater than 10. It is interesting to point out that both
SNPs, rs65245292 and rs28827533, have been identified by
BRVD as shown in Table 3. Although the SNP rs179455352 is not
included in Table 3, it has been selected by BRVD in the parallel
conquering step.
SKAT produced a small p-value for each of the 22 subsets,
ranging from 2:3|10{7 (chromosome 12) to 0.0016 (chromo-
some 21). According to the p-values, all chromosomes are
associated with heart, lung and blood diseases. This result suggests
that SKAT may be liberal in global association tests. To explore
the relationship between the p-value and the chromosome length,
we plot in Figure 8(b) the scatterplot of W{1(1{pi) versus log(Li),
where pi denotes the p-value of chromosome i, Li denotes the
length of chromosome i, and W denotes the CDF of the standard
normal distribution. The scatterplot indicates that SKAT tends to
produce a smaller p-value for a longer chromosome; that is, it
tends to be sensitive to the proportion of causal variants.
Figure 4. Type-I errors of BRVD for the simulated examples.
doi:10.1371/journal.pone.0069633.g004
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Figure 5. Marginal ROC curves for BRVD and BRI: Left panel: ROC curves with covariates adjusted; right panel: ROC curves with
covariates omitted.
doi:10.1371/journal.pone.0069633.g005
Figure 6. Illustrative plot for causal rare variants detection. The dashed curve shows the fitted density function for the marginal inclusion
scores of non-associated variants, and the vertical bar shows the classification rules at the FDR level 0.05 (solid line) and the FDR level 0.01 (dashed
line). The left panel is for cL~0:6 and the right panel is for cL~0:5.
doi:10.1371/journal.pone.0069633.g006
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Similarly, we plot in Figure 8(a) the scatterplot of
W{1(maxcL[L p(H1D i,cL)) versus log(Li) for BRVD, where Di
denotes the subset corresponding to chromosome i; and plot in
Figure 8(c) the scatterplot of W{1(p(H1D i)) versus log(Li) for
BRI, where p(H1D i) is calculated from the Bayesian factor with
the prior probabilities p(H0)~p(H1)~1=2. Although BRI is not
as sensitive to the chromosome length as SKAT, its results suggest
that it is pretty conservatives in global association tests. As
discussed above, the literature results show that chromosome 3
and chromosome 13 are also associated with heart, lung and blood
diseases, but BRI failed to identify these associations. In summary,
the comparison implies that BRVD outperforms both SKAT and
BRI for this real-data example.
Computational time
The computation time for the BRVD depends on the sample
size (n) and the number of variants (P). Table 4 recorded the CPU
time cost by BRVD on an Intel Xeon E5-2690 processor for
running 105 iterations under different settings of n and P. A linear
regression analysis of the CPU time versus n and P produces a R2
of 99.76%, which indicates an adequate fitting of the regression.
Both P and n are significant for the regression, and their p-values
are 4:9|10{6 and 7:4|10{4, respectively. Figure 9 plots the
CPU time of BRVD versus P for the EOMI data (with n~905). It
indicates a strong linear relationship between the CPU time and
P. Since the number of iterations is usually set to be proportional
to the value of P, this analysis implies that the CPU time of the
BRVD can increase as a quadratic function of P.
In analyzing the CPU time of BRVD, we fixed cL to 0.9. We
note that the CPU time of BRVD can slightly increase as cL
decreases for fixed values of n and P, because a smaller value of cL
tends to result in a larger model. However, the effect of cL is not
significant, because, under the control of multiplicity, the sizes of
the selected models are always tiny compared to the value of P.
The CPU time of the BRVD is dominated by the part of data
scanning that needs to be performed for each iteration.
Discussion
In this paper, we have developed a new Bayesian method, the
so-called BRVD, for detection of causal variants. The BRVD
simultaneously addresses two issues: (i) Are there any of the
variants associated with the disease, and (ii) Which variants, if any,
are driving the association. The BRVD is developed based on the
theory of posterior consistency, under which the causal variants
can be identified consistently. The numerical results indicate that
the BRVD is more powerful for global association tests than the
Table 2. BRVD results for the EOMI data.
Chromosome size cL mean SD
13 1811 0.9 0.9516 0.0046
2 8383 0.8 0.8059 0.0079
3 6534 0.9 0.7356 0.0080
19 8216 0.9 0.7069 0.0016
other 1271,12491 — 0.5,0.57 —
Size: the number of variants included in each chromosome; cL : the selected
value of cL ; mean: p(H1 D i ,cL), i.e., the average value of p(H1 D i ,cL) over five
independent runs at the selected value of cL ; SD: standard deviation of
p(H1 D i ,cL).
doi:10.1371/journal.pone.0069633.t002
Figure 7. Variant selection from Chromosome 13 for the EOMI data: The dashed curve shows the fitted density function for the
marginal inclusion scores of non-associated variants, and the vertical bar shows the classification rules at the FDR level 0.25.
doi:10.1371/journal.pone.0069633.g007
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existing methods, such as CMC, WSS, SKAT, C-alpha, RARE-
COVER, VT, and BRI, and also more powerful for detection of
causal variants than the BRI method. In this paper, we have also
developed a parallel version of BRVD based on the strategy of
divide-and-conquer. The parallel BRVD can be conveniently used
for the datasets for which the number of variants is extremely
large.
Since the BRVD is developed under the framework of logistic
regression, it can be directly applied to identify gene-gene and
gene-environment interactions by including in the model some
interaction terms of SNP-SNP and SNP-covariates. A gene-gene
and/or gene-environment interaction network can then be
constructed. This method is very flexible, depending on the
specification of interaction terms. For example, to explore complex
higher-order interactions, a partially linear tree-based regression
model [37] may be used.
Although BRVD has a high power for both the global
association tests and causal variants detection, its power can be
further improved by employing a more sophisticated weighting
scheme for the variants. The current weighting scheme depends
on the MAF only. In the future, one may incorporate other
biological information, e.g., the gene information, into the
weighting scheme. This may help further to identify the causal
variants whose MAFs are extremely low. In the current
Table 3. Top 14 variants identified by BRVD for the EOMI data at a FDR level of 0.2.
No. Variant Gene Chrom MAF No. Variant Gene Chrom MAF
1 rs65245292 SLC1A4 2 1.38% 8 rs194325058 TMEM44 3 3.26%
2 rs194408716 FAM43A 3 2.54% 9 rs28827533 PLB1 2 1.05%
3 rs39586979 C13orf23 13 2.76% 10 rs19961331 EFHB 3 4.81%
4 rs39424253 FREM2 13 3.76% 11 rs94197611 GPC6 13 0.99%
5 rs51994587 PCBP4 3 1.33% 12 rs128695828 NO-Gene 3 1.49%
6 rs39424254 FREM2 13 3.76% 13 rs242610172 ATG4B 2 1.55%
7 rs549728 GZMM 19 2.38% 14 rs57867517 ZNF304 19 0.94%
doi:10.1371/journal.pone.0069633.t003
Figure 8. Significance of global association tests versus chromosome length for the EOMI data: (a) BRVD; (b) SKAT; and (c) BRI.
doi:10.1371/journal.pone.0069633.g008
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implementation of the BRVD, the SAMC algorithm is used for
sampling from the posterior. At each iteration, a variant is
randomly selected to undergo a model update of variant addition,
deletion, or exchange. In the future, a SAMC algorithm with an
adaptive proposal may be used. The new version of SAMC allows
one to select a variant for model update based on the working
estimate of marginal inclusion probabilities. In the limit case, the
new version of SAMC will update the model according to the
marginal inclusion probabilities of all variants. Therefore, it can
converge faster than the standard version of SAMC.
For global association tests, the BRVD can also be used in
conjunction with other frequentist methods, such as SKAT, if one
is interested in a p-value measurement for the significance of the
test. One can first apply the BRVD to select a subset of variants
and then conduct the association test on the selected subset of
variants using the frequentist method. Since all the existing rare
variant testing methods seem to be sensitive to the proportion of
causal variants [38], the combined use of the BRVD and
frequentist methods can generally reduce the sensitivity of the
test methods to the proportion of causal variants.
The BRVD is general in the sense that it can be used for rare
variants, common variants, and also a joint analysis of common
and rare variants. In the case of joint analysis, its power for
detecting rare variants will not be affected much if ci in (9) is
chosen appropriately as an increasing function of MAF. We note
that in the literature some other Bayesian variable selection
methods have also been developed and can potentially be used for
variant selection [39,40,41]. However, none of these methods is
directly comparable with BRVD. The method [39] is developed
for linear regression under the framework of large-n-small-P, and
thus cannot be applied to the small-n-large-P logistic regression
problems considered in this paper. The method [40] is developed
for linear regression, although for the small-n-large-P problems;
hence, it cannot be compared with BRVD for logistic regression.
The method [41] aims to identify biomarkers, for which the model
incorporates the biological information on known pathways and
gene-gene networks. Since these information are not available for
the problems considered in this paper, this method cannot be
directly compared with BRVD. Also, we note that although
BRVD and the methods [40,41] are all applicable to the small-n-
large-P problems, BRVD has a theoretical advantage over the
other two methods: BRVD is consistent, i.e., the causal variables
Table 4. CPU time cost by the BRVD on an Intel Xeon E5-2690
processor (2.9 GHz) for running 105 iterations.
Case n P CPU(s)
1 500 600 7.67
2 905 1,271 17.21
3 905 1,811 19.02
4 905 6,534 26.99
5 905 8,383 29.88
6 905 11,491 34.73
7 905 24,944 53.82
n: sample size; P: number of variants.
doi:10.1371/journal.pone.0069633.t004
Figure 9. The CPU time of BRVD versus the number of variants for the EOMI data (with n~905).
doi:10.1371/journal.pone.0069633.g009
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can be identified by it in probability 1 as the sample size n??;
while this is unclear for the other two methods.
In this paper, BRVD is developed for dichotomous phenotypes
only. The framework of BRVD can be easily extended to
continuous phenotypes. For continuous phenotypes, linear regres-
sion can be used to relate the phenotype to the variants, and
appropriate prior distributions that lead to the posterior consis-
tency need to be specified for the model and model specific
parameters. Alternatively, one can impose a non-local prior on the
model parameters as in [42]. Under the non-local prior, it can be
shown that the causal variants can be consistently identified if the
total number of variants is bounded by the number of subjects.
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